Patients currently taking Chantix should consult with their doctor to confirm if they received an affected lot, and if appropriate, about alternative treatment options. Pfizer believes the benefit/risk profile of CHANTIX remains positive. iii CHANTIX has a safety profile that has been established over 15 years of marketing authorization and through a robust clinical program. ii Smoking is also associated with many other cancers. People who smoke cigarettes are 15 to 30 times more likely to get lung cancer than people who do not smoke. iĬhantix is a treatment to help patients quit smoking and is intended for short term use. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time. Everyone is exposed to some level of nitrosamines. Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables. The health benefits of stopping smoking outweigh the theoretical potential cancer risk from the nitrosamine impurity in varenicline. Long-term ingestion of N-nitroso-varenicline may be associated with a theoretical potential increased cancer risk in humans, but there is no immediate risk to patients taking this medication. Pfizer is voluntarily recalling an additional four lots of Chantix 0.5mg/1 mg Tablets to the patient (consumer/user) level due to the presence of a nitrosamine, N-nitroso-varenicline, above the Pfizer established Acceptable Daily Intake (ADI) level. Please look at the time stamp on the story to see when it was last updated. This is an archived article and the information in the article may be outdated.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |